MMWR Morb Mortal Wkly Rep. 2024 Oct 10;73(40):890-895. doi: 10.15585/mmwr.mm7340a1.
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that develops during childhood and can last into adulthood. Data from the National Center for Health Statistics Rapid Surveys System collected during October-November 2023 were used to estimate the prevalence of ADHD diagnosis and treatment among U.S. adults. In 2023, an estimated 15.5 million U.S. adults (6.0%) had a current ADHD diagnosis based on self-report; approximately one half received the diagnosis at age ≥18 years. Approximately one third of adults with ADHD took a stimulant medication to treat their ADHD in the previous year, 71.5% of whom had difficulty getting their ADHD prescription filled because it was unavailable. Approximately one half of adults with ADHD have ever used telehealth for ADHD-related services. Telehealth might have benefits for persons with ADHD, including helping them access behavioral treatment or medication prescriptions for ADHD. This report provides national estimates of the prevalence and treatment of ADHD among U.S. adults to help guide clinical care and regulatory decision-making for ADHD among U.S. adults.
注意缺陷多动障碍(ADHD)是一种神经发育障碍,在儿童时期发展,并可持续到成年期。使用国家健康统计中心快速调查系统在 2023 年 10 月至 11 月期间收集的数据来估计美国成年人中 ADHD 的诊断和治疗的流行率。2023 年,据自我报告估计,有 1550 万美国成年人(6.0%)目前被诊断患有 ADHD;大约有一半人在≥18 岁时被诊断出患有该疾病。大约三分之一的 ADHD 成年人在过去一年中服用兴奋剂药物来治疗他们的 ADHD,其中 71.5%的人因 ADHD 处方药物缺货而难以获得处方。大约有一半的 ADHD 成年人曾经使用过远程医疗来获取 ADHD 相关服务。远程医疗可能对 ADHD 患者有益,包括帮助他们获得 ADHD 的行为治疗或药物处方。本报告提供了美国成年人中 ADHD 的流行率和治疗情况的全国估计数据,以帮助指导美国成年人 ADHD 的临床护理和监管决策。